Therefore, in a subcutaneous tumor model established with Panc02 cells, we evaluated the antitumor efficacy of αMSLN in combination with a CD8+ T cell‐blocking antibody (Figure S4A, Supporting Information). The gene discussed is CD8A; the disease is neoplasm.